Genetic tests showed that certain patients were predisposed to brain injuries if they took the drugs. That information ...

Amgen will launch its biosimilar version of Regeneron's blockbuster eye care drug Eylea following a U.S. appeals court ruling ...

Amgen will launch its biosimilar version of Regeneron's blockbuster eye care drug Eylea following a U.S. appeals court ruling ...

A Maryland drug affordability board can move forward with a plan to cap how much the state and local governments pay for ...

An interim analysis from a long-term open-label extension study has underlined the clinical efficacy and safety of ...

Amgen (NASDAQ: AMGN) stock is up 13% this year but has struggled to break out above a tight trading range in recent months.

As for Lilly ( LLY ), Bernstein said its outperform rating “hinges on what they can do with the cash they generate from ...

Regeneron Pharmaceutical (NASDAQ:REGN) fell 2% after a court rejected its request for a temporary injunction blocking sales ...

Patients with inflammatory bowel disease (IBD) who initially responded to the investigational monoclonal antibody ...

U.S. Public Interest Research Group, Service Employees International Union (SEIU) and others expressed concerns in a letter ...

On September 23, 2024, Judge Kleeh of the Northern District of West Virginia denied Regeneron Pharmaceuticals, Inc.’s ...

TD Cowen analyst Yaron Werber maintained a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $383.00. Yaron ...